BCL2L11 and antiphospholipid syndrome: Bim (apoptotic activator) and APS (antiphospholipid syndrome related) nodes showed relatively high rates of structural evolution and very low rate of regulatory evolution, whereas BCL-XL (apoptosis inhibitor) node showed a medium rate of the structural and high rate of regulatory evolution.